| Quarterly Financials | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 358 | 553 | 522 | 497 | 563 | 598 |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 |
| EBITDA | 140 | 223 | 184 | 209 | 214 | 266 |
| Operating Profit % | 36 % | 37 % | 32 % | 40 % | 35 % | 40 % |
| Depreciation | 19 | 20 | 20 | 30 | 27 | 34 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 |
| Profit Before Tax | 118 | 200 | 161 | 178 | 186 | 230 |
| Tax | 36 | 38 | 37 | 96 | 51 | 56 |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 |
| EPS in ₹ | 1.47 | 2.90 | 2.22 | 1.48 | 2.43 | 3.09 |
Anthem Biosciences
Anthem Biosciences
632.60
-1.70
(-0.27%)
Market Cap
₹35,527.45 Cr
PE Ratio
70.49
Volume
2,60,057.00
Day High - Low
₹641.00 - ₹630.20
52W High-Low
₹873.50 - ₹624.05
Key Fundamentals
Market Cap
35,527.45 Cr
EPS
8.07
PB Ratio
13.22
Book Value
49.01
EBITDA
756.60
Dividend Yield
0.00 %
Industry
Healthcare Sector
Biotechnology ROE Growth %
-
Debt to Equity
0.08
Analyst Rating and Forecast
- By Refinitiv from2 analysts
Actual
Company News
View All News
Anthem Biosciences Reports Strong H1 FY26 Results with 26% Revenue Growth and 41.4% EBITDA MarginNov 12, 2025
Anthem Biosciences Limited delivered consolidated revenue of Rs. 1,090 Cr for the half-year ended September 30, 2025, with CRDMO business contributing Rs. 926 Cr and specialty ingredients Rs. 163 Cr. The company achieved EBITDA of Rs. 480 Cr with a margin of 41.4% and PAT of Rs. 309 Cr representing a 26.6% margin. Net cash position improved to Rs. 993 Cr. The company expanded its commercial molecules from 10 to 14 during the period, while late-phase molecules reduced from 10 to 6 as four moved to commercial status. Anthem commissioned CP6 and CP7 blocks adding 130 kiloliters capacity in Unit-II, with total CAPEX of Rs. 182 Cr. The company is progressing on Unit-IV development with planned Rs. 1,000 Cr investment over two years, targeting 400 kiloliters custom synthesis and 100 kiloliters fermentation capacity. Management expressed confidence in maintaining historical 20% CAGR growth trajectory and expects to operate at the upper end of 36%-37% EBITDA margin guidance.
Anthem Biosciences Limited reported violations of its insider trading code by two designated persons to stock exchanges. Srinivas L sold 674 equity shares during a trading window closure period that began October 1, 2025, through his pledgee agent despite instructing them not to sell during the restricted period. Bhuvaneswari sold 5,000 equity shares worth Rs. 41,75,000 without obtaining preclearance approval, as her previous approval had expired while she was on medical leave. The Audit Committee issued warning letters to both individuals and obtained acknowledgement letters confirming future compliance with the company's code of conduct. Both violations were treated seriously by the company, with warnings that future breaches will attract stricter disciplinary action.
Anthem Biosciences Reports Mixed Performance with Revenue Growth but Profit Decline in Q2 FY2026
Nov 08, 2025
Nov 08, 2025Anthem Biosciences Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025. On a consolidated basis, the company reported total income of Rs. 5,500.27 million for Q2 FY2026 compared to Rs. 5,249.56 million in the same quarter last year. However, profit before tax declined to Rs. 2,296.03 million from Rs. 1,995.33 million year-over-year. For the half-year period, total income increased to Rs. 10,902.36 million from Rs. 8,635.50 million in the previous year, while profit before tax rose to Rs. 4,158.51 million from Rs. 3,175.09 million. The company operates through two main segments: CRDMO (Contract Research, Development and Manufacturing Organization) which generated Rs. 4,658.13 million in Q2, and Speciality Ingredients contributing Rs. 842.14 million. The Board of Directors approved these results in their meeting held on November 8, 2025. The company's equity shares are listed on NSE and BSE since July 21, 2025, following its IPO.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
632.60 | #1 35,527.45 | #3 70.49 | #1 1,930.30 | #1 30.15 | #1 451 | #2 7.10 | 27.25 | |
314.95 | 3,523.70 | 24.09 | 670.00 | 1.44 | 134 | #1 33.83 | 46.78 | |
149.05 | 205.76 | -897.22 | 4.30 | - | 0 | -102.70 | 48.22 | |
30.36 | 69.62 | #1 8.25 | 51.50 | 13.19 | 7 | -82.69 | 29.54 | |
0.64 | 27.12 | 73.00 | 24.40 | 14.55 | 0 | -100.00 | 21.66 | |
29.65 | 9.29 | 92.03 | 0.84 | #1 320.00 | 0 | -100.00 | 46.86 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
30.15 %
Net Income Growth
22.87 %
Cash Flow Change
198.49 %
ROE
-1.83 %
ROCE
13.75 %
EBITDA Margin (Avg.)
2.22 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 787 | 1,034 | 1,619 | 2,015 | 2,398 | 2,808 |
| Fixed Assets | 306 | 361 | 329 | 449 | 483 | 705 |
| Current Assets | 403 | 616 | 1,098 | 1,323 | 1,482 | 1,737 |
| Capital Work in Progress | 50 | 19 | 154 | 164 | 345 | 297 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 |
| Other Assets | 333 | 445 | 863 | 903 | 1,099 | 1,373 |
| Total Liabilities | 787 | 1,034 | 1,619 | 2,015 | 2,398 | 2,808 |
| Current Liabilities | 247 | 285 | 223 | 164 | 339 | 326 |
| Non Current Liabilities | 118 | 47 | 41 | 110 | 135 | 72 |
| Total Equity | 422 | 702 | 1,355 | 1,741 | 1,925 | 2,410 |
| Reserve & Surplus | 414 | 693 | 1,346 | 1,627 | 1,813 | 2,298 |
| Share Capital | 8 | 9 | 9 | 114 | 112 | 112 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 9 | 18 | 308 | -6 | -159 | 133 |
| Investing Activities | -109 | -196 | -205 | -376 | -222 | -152 |
| Operating Activities | 166 | 278 | 333 | 306 | 140 | 418 |
| Financing Activities | -48 | -63 | 181 | 64 | -77 | -134 |
Share Holding
| % Holding | Dec 2024 | Jul 2025 | Sept 2025 |
| Promoter | 77.23 % | 76.88 % | 74.69 % |
| FIIs | 0.00 % | 0.00 % | 1.67 % |
| DIIs | 0.00 % | 0.00 % | 7.22 % |
| Government | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 0.00 % | 9.61 % |
| Others | 22.77 % | 23.12 % | 6.81 % |
| No of Share Holders | 16 | 761 | 2,17,681 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Aug 2025 |  Quarterly Result Announcement | NA | 13 Aug 2025 | 749.65 | 743.45 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 742.15 | 697.00 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 12, 2025
Nov 12, 2025Intimation Of Violation Under CompanyS Code Of Conduct To Regulate Monitor And Report Trading By Designated Persons As Required Under SEBI (Prohibition Of Insider Trading) Regulations 2015 (SEBI PIT Regulations)Nov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 08, 2025
Nov 08, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 08, 2025
Nov 08, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On Saturday November 08 2025Nov 08, 2025
Nov 08, 2025Outcome Of The Board Meeting Held On Saturday November 08 2025Nov 08, 2025
Nov 08, 2025Intimation Of Violation Under CompanyS Code Of Conduct To Regulate Monitor And Report Trading By Designated Persons As Required Under SEBI (Prohibition Of Insider Trading) Regulations 2015 (SEBI PIT Regulations)Oct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 23, 2025
Oct 23, 2025Board Meeting Intimation for The Financial Results For Quarter And Half Year Ended September 30 2025Oct 23, 2025
Oct 23, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 06, 2025
Oct 06, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 19, 2025
Sep 19, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 15, 2025
Sep 15, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Aug 18, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Aug 13, 2025Outcome Of Board Meeting Held On Wednesday August 13 2025Aug 13, 2025
Aug 13, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday August 13 2025Aug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 08, 2025
Aug 08, 2025Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results For The Quarter Ended June 30 2025Aug 08, 2025
Aug 08, 2025Intimation Under Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation 2015Jul 21, 2025
Jul 21, 2025Announcement Under Regulation 7(1) Of The Securities And Exchange Board Of India (Listing Obligation And Disclosures Requirements) Regulation 2015Jul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Jul 21, 2025
Jul 21, 2025Closure of Trading WindowJul 21, 2025
Jul 21, 2025Appointment of Company Secretary and Compliance OfficerJul 21, 2025
Jul 21, 2025Listing of Equity Shares of Anthem Biosciences LtdJul 21, 2025
Jul 21, 2025Mutual Fund Holdings
Aditya Birla Sun Life ELSS Tax Saver Direct-Growth 
Kotak Small Cap Fund Direct-Growth 
Axis Small Cap Fund Direct-Growth 
Edelweiss Recently Listed IPO Fund Direct-Growth 
HDFC Pharma And Healthcare Fund Direct - Growth 
Mahindra Manulife Mid Cap Fund Direct - Growth 
Mirae Asset Small Cap Fund Direct-Growth 
LIC MF Dividend Yield Fund Direct - Growth 
UTI Healthcare Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Bandhan Aggressive Hybrid Fund Direct-Growth 
PGIM India Healthcare Fund Direct-Growth 
Union Midcap Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 27.60
ATR(14)
Less Volatile 20.38
STOCH(9,6)
Oversold 7.56
STOCH RSI(14)
Oversold 3.59
MACD(12,26)
Bearish -3.03
ADX(14)
Strong Trend 39.04
UO(9)
Bearish 34.66
ROC(12)
Downtrend And Accelerating -8.94
WillR(14)
Oversold -88.79
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
